VNDA Financial Facts
Product sales: 38.48MCost of sales, product: 6.99M
See Full Income Statement
Intangible asset, net: 29.92M
Total liabilities: 79.28M
See Full Balance Sheet
Vanda Pharma (VNDA) Earnings
|
Expand Research on VNDA
| Next EPS Date | 11/4/26 | EPS Growth Rate | -60.5% |
|---|---|---|---|
| Average EPS % Beat Rate | -41.3% | Revenue Growth Rate | +24.1% |
| Average % Move 1-Wk after EPS | -11.4% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
11/4/26  |
Q326 | N/A | -$0.61 | N/A | N/A | $69.8M | = | N/A | N/A | ||
| 8/5/26 | Q226 | -$1.04 | -$0.60 | -$0.44 | $50.52M | $61.78M | = |  | | Details | |
| 5/6/26 | Q126 | -$0.82 | -$0.69 | -$0.13 | $51.72M | $55.04M | = | | | Details | |
| 2/11/26 | Q425 | -$1.81 | -$0.98 | -$0.83 | $33.22M | $59.28M | = | | | Details | |
| 10/29/25 | Q325 | -$0.38 | -$0.43 | +$0.05 | $56.26M | $58.83M | = | | | Details | |
| 7/31/25 | Q225 | -$0.46 | -$0.29 | -$0.17 | $52.59M | $55.1M | = | | | Details | |
| 5/7/25 | Q125 | $0.00 | -$0.02 | +$0.02 | $50.04M | $61.02M | = | | | Details | |
| 5/2/25 |
Q125 | N/A | -$0.02 | N/A | N/A | $61.02M | = | N/A | N/A |
